<DOC>
	<DOCNO>NCT00604357</DOCNO>
	<brief_summary>Background : Patients undergo liver transplantation preexist renal dysfunction prone renal impairment early postoperative use Calcineurin-inhibitors . However , little scientific evidence safety efficacy de novo CNI free regimen patient impaired renal function undergo liver transplantation . The objective study evaluate de novo calcineurin-inhibitor-free immunosuppressive regimen base induction therapy anti-CD25 monoclonal anti- body , mycophenolate mofetil ( MMF/MPA ) , mTOR-inhibition determine safety investigate preliminary efficacy patient impaired renal function time liver transplantation . Methods/Design : Patients older 18 year renal impairment time liver transplantation due hepatorenal syndrome , eGFR &lt; 50 ml/min and/or serum creatinine level &gt; 1.5 mg/dL include . Patients receive combination therapy antiCD25-monoclonal antibody , MMF , steroid delay sirolimus ( day 10 ) evaluate regard incidence steroid resistant acute rejection within first 30 day liver transplantation primary endpoint . The study design prospective two-step trial require maximum 29 patient . In first step 9 patient include . If 8 patient show sign biopsy proven steroid resistant rejection , additional 20 patient include . If second step total 27 patient reach primary end-point regimen regard safe efficient . The follow period one year transplantation . The aim obtain safety efficacy data new innovative therapy regimen might basis large prospective randomize multicenter trial future .</brief_summary>
	<brief_title>CNI-free de Novo Protocol Patients Undergoing Liver Transplantation With Renal Impairment</brief_title>
	<detailed_description>Objectives study The objective study evaluate de novo CNI-free immunosuppressive regimen base induction therapy anti-CD25 monoclonal anti- body , mycophenolate mofetil ( MMF/MPA ) , delay mTOR-inhibition . The primary endpoint define incidence steroid-resistant acute rejection within first 30 day liver transplantation . Secondary objective include incidence acute rejection ( ) , number time acute rejection per patient within first year transplantation . A critical secondary endpoint development renal function 1 week , 1 , 3 , 6 12 month liver transplantation . This include information number patient require renal replacement therapy duration . During follow-up 1 year liver allograft function , infectious complication , treatment failure define introduction CNIs well side-effects affect hematopoetic system , tolerability , impaired wound-healing , incidence hepatic artery thrombosis mortality explicitly document investigate . Trial population The collective aiming patient older 18 year preexist renal impairment time liver transplantation . Patients eligible eGFR &lt; 50 ml/min ( Cockcroft-Gault ) and/or serum creatinine level &gt; 1.5 mg/dL . Follow-Up Every patient follow 1 year transplantation . The primary end-point 30 day transplantation ( Steroid resistant acute rejection ) . During first 30 day transplantation 9 visit laboratory value ( liver , renal metabolic function , sirolimus trough level ) , adverse event rejection episode record . Additionally ultrasound day 1 liver transplantation day 10 prior initiation sirolimus exclude hepatic artery thrombosis . Between day 30 1 year liver transplantation patient follow evaluate long time outcome secondary objective trial .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients undergo primary liver transplantation . Patients older 18 year . Patients hepatorenal syndrome type I II eGFR &lt; 50 ml/min time point transplantation Serum creatinine level &gt; 1.5 mg/dL timepoint transplantation Patients pretransplant renal replacement therapy &gt; 14 day . Patients know hypersensitivity mTORinhibitors . Patients know hypersensitivity mycophenolate acid . Patients know hypersensitivity anti CD 25monoclonal antibody . Patients platelets &lt; 50.000/nl . Patients triglyceride &gt; 350 mg/dl cholesterol &gt; 300 mg/dl refractory optimal medical treatment prior initiation therapy mTOR inhibition . Severe systemic infection woundhealing disturbance prior inclusion . Multiple organ graft recipient . Patients sign hepatic artery stenosis directly prior initiation therapy Sirolimus . Patients psychological , familial , sociologic geographic condition potentially hamper compliance study protocol followup schedule . Patients guardianship ( e.g . individual able freely give informed consent ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>CNI free</keyword>
	<keyword>mTOR inhibition</keyword>
	<keyword>induction</keyword>
	<keyword>IL2 receptor antibody</keyword>
	<keyword>renal function</keyword>
	<keyword>liver transplantation</keyword>
</DOC>